Hosted on November 12, 2020 in partnership with Abeona Therapeutics, this webinar presented cutting edge clinical development updates towards the treatment of epidermolysis bullosa. The webinar featured presentations from Jean Tang, MD, PhD (Professor of Dermatology, Stanford University Medical Center and Principal Investigator, EB-101 pivotal Phase 3 VIITAL study) and Michael Amoroso (Chief Commercial Officer, Abeona) and moderated discussion.
EB-101 Clinical Development Update and Q&A Session, sponsored by Abeona Therapeutics
Thursday, November 12, 2020 8:00 AM PST / 11:00 AM EST
Speakers: Jean Tang, MD, PhD and Michael Amoroso
Jean Tang, MD, PhD
Professor of Dermatology, Stanford University Medical Center AND Principal Investigator, EB-101 pivotal Phase 3 VIITAL study
Dr. Tang’s research focuses on genetic skin diseases such as Basal Cell Nevus Syndrome and Epidermolysis Bullosa. She studies new ways to treat and prevent NSMC and melanoma. Dr. Tang has led or co-led the conduct and completion of 6 investigator initiated clinical trials in BCC and EB. She received her MD/PhD from Stanford (Biophysics), completed her dermatology residency at Stanford, and then went to UCSF for a 3 year post-doc in mouse genetics, while simultaneously pursuing formal coursework in biostatistics, epidemiology, and clinical trial design in the KL2 CTSI program.
Michael Amoroso, MBA
Chief Commercial Officer, Abeona
Michael Amoroso joined Abeona as Senior Vice President and Chief Commercial Officer in July 2020, bringing over 20 years of product commercialization experience in the biotechnology and pharmaceutical industries with a focus on cell and gene therapies, and a proven track record of launching innovative drugs for rare diseases.
Prior to joining Abeona, Mr. Amoroso held various senior level commercial positions at leading biopharmaceutical companies, including Kite, Eisai Inc., Celgene Corporation (now a subsidiary of Bristol-Myers Squibb Company), and Sanofi. At Kite, he was responsible for the company’s worldwide commercial organization leading the commercialization efforts for the autologous CAR T-cell therapy, YESCARTA®, and the future cell therapy pipeline. Before Kite, Mr. Amoroso was Senior Vice President, Americas for Eisai’s Commercial Oncology Business Group, where he was accountable for teams charged with creating and driving commercial strategy and implementation for the company’s approved products and earlier-stage assets. Previously, Mr. Amoroso worked at Celgene for six years in several commercial roles before serving as the organization’s Commercial Lead for CAR T-cell therapy programs. In this capacity, he helped Celgene develop an organizational model to commercialize cell therapies including specialized manufacturing and customer services for patients with lymphoma and myeloma. Before joining Celgene, Mr. Amoroso held various marketing and sales leadership positions over his 10-plus year tenure at Sanofi.
Mr. Amoroso earned his M.B.A. in Management from the Stern School of Business, New York University, and his B.A. in Biological Sciences, summa cum laude, from Rider University.
This webinar is being hosted by PeDRA and sponsored by Abeona Therapeutics. PeDRA will evaluate content for suitability for its audience but is not responsible for the creation of content, selection of speakers, or delivery of presentations. Please email us at email@example.com with any questions or concerns.